Telix reports 22% H1 2026 revenue growth, guides to upper end of FY targets
Telix posted $477M in first-half revenue and net profit of $38M, while advancing five late-stage clinical programs and a Regeneron collaboration.
Telix Pharmaceuticals filed its H1 2026 interim results presentation with the SEC on August 20, 2026, covering the six months ended June 30, 2026.
Group revenue increased by 22% to $477M driven by strong demand across our Precision Medicine portfolio.1 Within that, global revenue (ex-TMS) increased to $388M, up 25% YoY driven by Precision Medicine business market share gains.1 According to the presentation's key metrics slide, net profit was up $41M YoY at $38M, versus -$2M in H1 2025, and the cash balance was up 78% at $252M, versus $142M at Dec 31 2025.1
On the pipeline, the company said TLX591-Tx ProstACT Global reached FDA alignment on safety and Part 2 Protocol in mCRPC, while TLX101-Tx IPAX BrIGHT is dosing patients with recurrent glioblastoma and TLX250-Tx LUTEON is dosing patients with advanced ccRCC. TLX090-Tx SOLACE is dosing patients, and BiPASS is nearing completion of enrollment.1
Regulatory milestones include a secured Prescription Drug User Fee Act date for Pixclara of September 11, 2026, and a Pixlumi Marketing Authorization Application accepted for review in Europe.1 The company noted Zircaix and Pixclara brand names and launch are subject to final regulatory approval.1
Telix also disclosed it entered into a co-development and co-commercialization agreement with Regeneron to develop next-generation candidates,1 with an upfront payment of $40M from Regeneron1 reflected in other income.
For the full year, Telix said it is on track to deliver in line with the upper end of FY 2026 revenue guidance of $950M - $970M.1 R&D guidance range is set at $230M to $270M1 per the presentation's guidance slide.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.